SCHEMBL13576487

SCHEMBL13576487

O=[N+]([O-])c1cccc(/C=N\Nc2nc(Nc3ccc(Cl)cc3)nc(N3CCOCC3)n2)c1

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 5/20 0.81
▸ HTT P42858 6/20 0.65
▸ KMT2A Q03164 9/20 0.64
▸ MEN1 O00255 8/20 0.64
▸ MAPT P10636 8/20 0.64
▸ ALDH1A1 P00352 4/20 0.64
▸ TDP1 Q9NUW8 2/20 0.64
▸ AKR1C3 P42330 1/20 0.60
▸ AKR1C1 Q04828 1/20 0.60
▸ NPSR1 Q6W5P4 2/20 0.57
▸ CYP1A2 P05177 1/20 0.57
▸ CYP3A4 P08684 1/20 0.57
▸ CYP2C9 P11712 1/20 0.57
▸ CYP2C19 P33261 1/20 0.57
▸ L3MBTL1 Q9Y468 1/20 0.56
▸ SMN1; SMN2 Q16637 1/20 0.54
▸ GAA P10253 1/20 0.54
▸ RECQL P46063 1/20 0.54
▸ TEX264 Q9Y6I9 1/20 0.54
▸ CTSL P07711 2/20 0.54

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13944051 0.83 LMNA (0.70) LMNAHTTKMT2AMEN1MAPT
SCHEMBL19016864 0.81 KMT2A (0.58) LMNAHTTKMT2AMEN1MAPT
SCHEMBL13942699 0.81 KMT2A (0.77) LMNAHTTKMT2AMEN1MAPT
SCHEMBL19609053 0.80 CA12 (0.55) LMNAHTTKMT2AMEN1MAPT
SCHEMBL19002882 0.78 KMT2A (0.70) LMNAHTTKMT2AMEN1MAPT
SCHEMBL4254863 0.78 LMNA (0.75) LMNAHTTKMT2AMEN1MAPT
SCHEMBL4254859 0.78 LMNA (0.75) LMNAHTTKMT2AMEN1MAPT
SCHEMBL22737807 0.77 MAPT (0.68) LMNAHTTKMT2AMEN1MAPT
SCHEMBL8909541 0.77 KMT2A (0.57) LMNAHTTKMT2AMEN1MAPT
SCHEMBL22737374 0.77 MAPT (0.62) LMNAHTTKMT2AMEN1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8507546-B2 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) 2013-08-13 — — US disclosed
US-8507546-B2 Use of inhibitors of scavenger receptor class proteins for the treatment of infectious diseases INSTITUTO DE MEDICINA MOLECULAR, FACULDADE DE MEDICINA DA UNIVERSIDADE DE LISBOA (PT) 2013-08-13 — — US disclosed
US-20090324580-A1 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases CENIX BIOSCIENCE GMBH (DE) 2009-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090324580-A1 Use of Inhibitors of Scavenger Receptor Class Proteins for the Treatment of Infectious Diseases SCARB1, MSR1, HAVCR2 LMNA 2485/4885HTT 3330/4885KMT2A 4757/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback